Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biofrontera Inc WT (BFRIW)

Biofrontera Inc WT (BFRIW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

BFRI : 1.0450 (+3.47%)
BFRIW : 0.0851 (-29.08%)
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

BFRI : 1.0450 (+3.47%)
BFRIW : 0.0851 (-29.08%)
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

BFRI : 1.0450 (+3.47%)
BFRIW : 0.0851 (-29.08%)
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

BFRI : 1.0450 (+3.47%)
BFRIW : 0.0851 (-29.08%)
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

BFRI : 1.0450 (+3.47%)
BFRIW : 0.0851 (-29.08%)
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

BFRI : 1.0450 (+3.47%)
BFRIW : 0.0851 (-29.08%)
Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH

Patent Improves Differentiated Profile of Ameluz-PDT by Expected Reduced Pain Intensity while Maintaining Efficacy WOBURN, Mass., Aug. 01, 2022 (GLOBE...

BFRI : 1.0450 (+3.47%)
BFRIW : 0.0851 (-29.08%)
Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement

WOBURN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...

BFRIW : 0.0851 (-29.08%)
BFRI : 1.0450 (+3.47%)
Biofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing Excellence

Named Among the 10 Fastest-Growing Life Sciences Companies to Watch in 2022 by CIOCoverage Magazine New Ameluz® Marketing Campaign Receives Gold 2022...

BFRI : 1.0450 (+3.47%)
BFRIW : 0.0851 (-29.08%)
Biofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 Conference

WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...

BFRIW : 0.0851 (-29.08%)
BFRI : 1.0450 (+3.47%)

Barchart Exclusives

Xpeng Motors Stock Price Prediction 2025: Is XPEV a Buy or Sell?
Despite having rallied from its 2024 lows, Xpeng Motors shares are in the red in 2024. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar